CSIMarket
 


Histogen Inc   (HSTO)
Other Ticker:  
 

Histogen Inc 's Working Capital Ratio

HSTO's quarterly Working Capital Ratio and Current Assets, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2023, Working Capital Ratio fell to 4.05 below Histogen Inc average.

Within Major Pharmaceutical Preparations industry 271 other companies have achieved higher Working Capital Ratio than Histogen Inc in third quarter 2023. While Working Capital Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from 290 to 1110.

Explain Working Capital Ratio
How much in Current Assets HSTO´s has?
What is the value of HSTO´s Current Liabilities?


HSTO Working Capital Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Change 14.92 % -23.89 % -59.29 % -57.25 % -54.3 %
Y / Y Current Assets Change -66.61 % -44.94 % -58.84 % -37.73 % -24.97 %
Working Capital Ratio MRQ 4.05 11.75 9.74 13.51 13.93
HSTO's Total Ranking # 1110 # 290 # 497 # 227 # 310
Seq. Current Liabilities Change 91.48 % -35.35 % 9.34 % -15.09 % 26.81 %
Seq. Current Assets Change -34.07 % -22 % -21.17 % -17.64 % 8.72 %



Working Capital Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 272
Healthcare Sector # 494
Overall Market # 1110


Working Capital Ratio Statistics
High Average Low
20.35 8.48 1.37
(Mar 31 2020)   (Jun 30 2013)




Financial Statements
Histogen Inc 's Current Liabilities $ 1 Millions Visit HSTO's Balance sheet
Histogen Inc 's Current Assets $ 5 Millions Visit HSTO's Balance sheet
Source of HSTO's Sales Visit HSTO's Sales by Geography


Cumulative Histogen Inc 's Working Capital Ratio

HSTO's Working Capital Ratio for the trailling 12 Months

HSTO Working Capital Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities TTM Growth 14.92 % -23.89 % -59.29 % -57.25 % -54.3 %
Y / Y Current Assets TTM Growth -66.61 % -44.94 % -58.84 % -37.73 % -24.97 %
Working Capital Ratio TTM 9.14 12.29 13.25 12.24 11.09
Total Ranking TTM # 3829 # 3902 # 3913 # 2471 # 399
Seq. Current Liabilities TTM Growth 91.48 % -35.35 % 9.34 % -15.09 % 26.81 %
Seq. Current Assets TTM Growth -34.07 % -22 % -21.17 % -17.64 % 8.72 %


On the trailing twelve months basis Due to jump in Current Liabilities in the III Quarter 2023 to $1.35 millions, cumulative Working Capital Ratio decreased to 9.14 above the HSTO average Working Capital Ratio.
Working Capital Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 484 other companies have achieved higher Working Capital Ratio than Histogen Inc . While Working Capital Ratio overall ranking has improved so far to 3829, from total ranking during the twelve months ending second quarter 2023 at 3902.

Explain Working Capital Ratio
How much in Current Assets HSTO´s has?
What is the value of HSTO´s Current Liabilities?

TTM Working Capital Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 485
Healthcare Sector # 1009
Within the Market # 3829


trailing twelve months Working Capital Ratio Statistics
High Average Low
10.85 6.15 2.42
(Mar 31 2023)   (Mar 31 2019)




Companies with similar Working Capital Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Working Capital RatioSep 30 2023 MRQ Current AssetsSep 30 2023 MRQ Current Liabilities
Atai Life Sciences N v   11.12 $ 215.825  Millions$ 19.403  Millions
Pasithea Therapeutics Corp   11.11 $ 20.771  Millions$ 1.869  Millions
Lipocine Inc   10.98 $ 24.614  Millions$ 2.241  Millions
Nkarta Inc   10.97 $ 281.188  Millions$ 25.640  Millions
Kinnate Biopharma Inc   10.80 $ 170.301  Millions$ 15.774  Millions
Virios Therapeutics Inc   10.77 $ 5.249  Millions$ 0.487  Millions
Xencor Inc  10.77 $ 571.176  Millions$ 53.041  Millions
Xenetic Biosciences Inc   10.53 $ 11.257  Millions$ 1.069  Millions
Actinium Pharmaceuticals Inc   10.50 $ 85.596  Millions$ 8.150  Millions
Milestone Pharmaceuticals inc   10.45 $ 84.797  Millions$ 8.114  Millions
Structure Therapeutics Inc   10.45 $ 209.959  Millions$ 20.091  Millions
Lianbio  10.06 $ 257.805  Millions$ 25.627  Millions
Annexon Inc   9.85 $ 169.169  Millions$ 17.170  Millions
Scpharmaceuticals Inc   9.75 $ 104.339  Millions$ 10.703  Millions
Syndax Pharmaceuticals Inc   9.73 $ 380.974  Millions$ 39.174  Millions
Werewolf Therapeutics Inc   9.64 $ 139.258  Millions$ 14.439  Millions
Tff Pharmaceuticals Inc   9.54 $ 10.893  Millions$ 1.142  Millions
Amylyx Pharmaceuticals Inc   9.52 $ 434.110  Millions$ 45.617  Millions
Centessa Pharmaceuticals Plc  9.51 $ 332.453  Millions$ 34.954  Millions
Reneo Pharmaceuticals Inc   9.49 $ 128.772  Millions$ 13.563  Millions
Phathom Pharmaceuticals Inc   9.46 $ 226.726  Millions$ 23.979  Millions
Bullfrog Ai Holdings Inc   9.43 $ 4.208  Millions$ 0.446  Millions
Adicet Bio Inc   9.40 $ 185.883  Millions$ 19.768  Millions
Aerovate Therapeutics Inc   9.34 $ 137.603  Millions$ 14.725  Millions
Allakos Inc   9.31 $ 218.279  Millions$ 23.450  Millions
Cytokinetics Incorporated  9.28 $ 561.416  Millions$ 60.487  Millions
Igm Biosciences Inc   9.27 $ 398.395  Millions$ 42.965  Millions
Ac Immune Sa  9.22 $ 125.153  Millions$ 13.576  Millions
Lexaria Bioscience Corp   9.17 $ 2.200  Millions$ 0.240  Millions
Point Biopharma Global Inc   9.14 $ 353.247  Millions$ 38.666  Millions

Date modified: 2023-11-12T11:17:11+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com